KRAS and non-small cell lung carcinoma: Our findings suggest a long-term benefit of pembrolizumab monotherapy for advanced NSCLC with PD-L1 TPS ≥ 50% in real-world settings in the US, particularly for patients with good performance status at the start of therapy, irrespective of KRAS mutation status.